CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation

PURPOSE: Liver transplantation is the treatment of choice for patients with end-stage liver disease. Due to the between- and within-individual pharmacokinetic variability in tacrolimus, used to prevent rejection after transplantation, it is difficult to predict the dose needed achieve the target lev...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Eunhee, Kim, Myeong gyu, Oh, Jung Mi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207397/
https://www.ncbi.nlm.nih.gov/pubmed/30498355
http://dx.doi.org/10.2147/TCRM.S184376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207397/
https://www.ncbi.nlm.nih.gov/pubmed/30498355
http://dx.doi.org/10.2147/TCRM.S184376

Ejemplares similares